GlobeNewswire Inc | Mar 18, 2021 08:01AM EDT

March 18, 2021

DUBLIN, Ireland, March 18, 2021 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218, an investigational, once-nightly formulation of sodium oxybate for treating excessive daytime sleepiness and cataplexy in adults with narcolepsy, announced today that members of the Avadel management team will participate in a fireside chat at Stifel's Third Annual CNS Day, which is being held on March 31st.

Avadels fireside chat is scheduled for 3 p.m. ET on Wednesday, March 31st. A live webcast of this event, as well as an archived recording, will be available at (click here), as well as on Avadels website, www.avadel.com, for 90 days from being made available.

Contacts:

Tom McHugh Chief Financial Officer Phone: (636) 449-1843 Email: tmchugh@avadel.com Tim McCarthy LifeSci Advisors, LLC Phone: (212) 915-2564 Email: tim@lifesciadvisors.com